Lv7
3438 积分 2022-03-03 加入
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
15小时前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
15小时前
已完结
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
5天前
已完结
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
9天前
已关闭
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
9天前
已关闭
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
9天前
已关闭
CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease
9天前
已完结
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
9天前
已完结
Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer
9天前
已完结
Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors
9天前
已完结
皖公网安备34019202002308
